Seng H Cheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11991345/publications.pdf

Version: 2024-02-01

81 papers	12,065 citations	46918 47 h-index	66788 78 g-index
81 all docs	81 docs citations	81 times ranked	10542 citing authors

#	Article	IF	Citations
1	Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine, 2018, 24, 1317-1323.	15.2	117
2	Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2699-2704.	3.3	165
3	Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, ddw124.	1.4	44
4	A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation, 2016, 3, 1-210.	0.9	22
5	Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Progress in Neurobiology, 2015, 125, 47-62.	2.8	63
6	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2015, 3, 684-691.	5.2	344
7	Dimorphic Effects of Transforming Growth Factor-Î² Signaling During Aortic Aneurysm Progression in Mice Suggest a Combinatorial Therapy for Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 911-917.	1.1	189
8	Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease. Human Gene Therapy, 2014, 25, 461-474.	1.4	135
9	Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9â€“Survival Motor Neuron 1 for Spinal Muscular Atrophy. Human Gene Therapy, 2014, 25, 619-630.	1.4	79
10	Systemic Delivery of a Peptide-Linked Morpholino Oligonucleotide Neutralizes Mutant RNA Toxicity in a Mouse Model of Myotonic Dystrophy. Nucleic Acid Therapeutics, 2013, 23, 109-117.	2.0	52
11	Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3537-3542.	3.3	203
12	A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis: TableÂ1. Thorax, 2013, 68, 1075-1077.	2.7	66
13	The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration toÂsheep. Biomaterials, 2013, 34, 10267-10277.	5.7	30
14	Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 217-228.	0.9	58
15	Gene Transfer to the CNS Is Efficacious in Immune-primed Mice Harboring Physiologically Relevant Titers of Anti-AAV Antibodies. Molecular Therapy, 2012, 20, 1713-1723.	3.7	22
16	Rapid identification of novel functional promoters for gene therapy. Journal of Molecular Medicine, 2012, 90, 1487-1496.	1.7	9
17	Mutant <i>GBA1</i> Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models. Neurodegenerative Diseases, 2012, 10, 195-202.	0.8	26
18	Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron, 2012, 74, 1031-1044.	3.8	635

#	Article	IF	Citations
19	Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 2012, 488, 111-115.	13.7	435
20	Assessment of the nuclear pore dilating agent transâ€cyclohexaneâ€1,2â€diol in differentiated airway epithelium. Journal of Gene Medicine, 2012, 14, 491-500.	1.4	6
21	IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiology of Disease, 2012, 45, 272-279.	2.1	41
22	Prospects for the gene therapy of spinal muscular atrophy. Trends in Molecular Medicine, 2011, 17, 259-265.	3.5	29
23	Acid Î²â€glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter Î±â€synuclein processing. Annals of Neurology, 2011, 69, 940-953.	2.8	276
24	Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer. Biomaterials, 2011, 32, 2614-2624.	5.7	29
25	CNS expression of glucocerebrosidase corrects Î±-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12101-12106.	3.3	282
26	Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy. Science Translational Medicine, 2011, 3, 72ra18.	5.8	437
27	Inhibition of osteoclastogenesis by prolyl hydroxylase inhibitor dimethyloxallyl glycine. Journal of Bone and Mineral Metabolism, 2010, 28, 510-519.	1.3	33
28	The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways. Biomaterials, 2010, 31, 2665-2672.	5.7	27
29	CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation, 2010, 120, 1253-1264.	3.9	252
30	Low-frequency ultrasound increases non-viral gene transfer to the mouse lung. Acta Biochimica Et Biophysica Sinica, 2010, 42, 45-51.	0.9	11
31	Limitations of the Murine Nose in the Development of Nonviral Airway Gene Transfer. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 46-54.	1.4	18
32	A hypoxic inducible factorâ€1Î± hybrid enhances collateral development and reduces vascular leakage in diabetic rats. Journal of Gene Medicine, 2009, 11, 390-400.	1.4	26
33	The role of doxorubicin in non-viral gene transfer in the lung. Biomaterials, 2009, 30, 1971-1977.	5.7	12
34	In vivo imaging of gene transfer to the respiratory tract. Biomaterials, 2008, 29, 1533-1540.	5.7	13
35	CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nature Biotechnology, 2008, 26, 549-551.	9.4	269
36	Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor Î±/retinoid X receptor. Biochemical and Biophysical Research Communications, 2007, 364, 567-572.	1.0	67

#	Article	IF	Citations
37	Identification of transfected cell types following non-viral gene transfer to the murine lung. Journal of Gene Medicine, 2007, 9, 184-196.	1.4	18
38	Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung. Journal of Gene Medicine, 2007, 9, 369-380.	1.4	42
39	Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respiratory Research, 2006, 7, 26.	1.4	59
40	Expression of constitutively stable hybrid hypoxia-inducible factor-1Î± protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. American Journal of Physiology - Cell Physiology, 2005, 288, C314-C320.	2.1	89
41	Formulation of Synthetic Gene Delivery Vectors for Transduction of the Airway Epithelium. , 2004, 245, 95-114.		0
42	Contribution of Toll-like Receptor 9 Signaling to the Acute Inflammatory Response to Nonviral Vectors. Molecular Therapy, 2004, 9, 241-248.	3.7	81
43	Partial correction of theÎ±-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. Journal of Gene Medicine, 2004, 6, 85-92.	1.4	22
44	Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. American Journal of Physiology - Renal Physiology, 2004, 287, F649-F657.	1.3	55
45	Hypoxia-Inducible Factor-1 Mediates Activation of Cultured Vascular Endothelial Cells by Inducing Multiple Angiogenic Factors. Circulation Research, 2003, 93, 664-673.	2.0	292
46	DNA Sequences in Cationic Lipid:pDNA-Mediated Systemic Toxicities. Human Gene Therapy, 2003, 14, 203-214.	1.4	36
47	CpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in Vivo. Molecular Therapy, 2002, 5, 731-738.	3.7	203
48	Adenovirus-Transduced Lung as a Portal for Delivering Î±-Galactosidase A into Systemic Circulation for Fabry Disease. Molecular Therapy, 2002, 5, 745-754.	3.7	37
49	Formulation of Synthetic Vectors for Cystic Fibrosis Gene Therapy. , 2002, 70, 585-598.		0
50	Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1Î±. Physiological Genomics, 2002, 8, 23-32.	1.0	54
51	Hypoxia Up-regulates Expression of Peroxisome Proliferator-activated Receptor Î³ Angiopoietin-related Gene (PGAR) in Cardiomyocytes: Role of Hypoxia Inducible Factor 1Î±. Journal of Molecular and Cellular Cardiology, 2002, 34, 765-774.	0.9	128
52	Stabilization of Vascular Endothelial Growth Factor mRNA by Hypoxia-Inducible Factor 1. Biochemical and Biophysical Research Communications, 2002, 291, 908-914.	1.0	125
53	High and Sustained Transgene Expression in Vivo from Plasmid Vectors Containing a Hybrid Ubiquitin Promoter. Molecular Therapy, 2001, 4, 75-82.	3.7	129
54	Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs. Molecular Therapy, 2000, 1, 255-262.	3.7	211

#	Article	IF	Citations
55	Cationic Lipid Structure and Formulation Considerations for Optimal Gene Transfection of the Lung. Journal of Drug Targeting, 2000, 7, 453-469.	2.1	35
56	Characterization of the oligosaccharide structures associated with the cystic fibrosis transmembrane conductance regulator. Glycobiology, 2000, 10, 1225-1233.	1.3	31
57	Comprehensive Analysis of the Acute Toxicities Induced by Systemic Administration of Cationic Lipid:Plasmid DNA Complexes in Mice. Human Gene Therapy, 2000, 11, 2493-2513.	1.4	218
58	Nitric oxide inhibits heterologous CFTR expression in polarized epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L89-L96.	1.3	20
59	Restoration of Cyclic Adenosine Monophosphateâ€“Stimulated Chloride Channel Activity in Human Cystic Fibrosis Tracheobronchial Submucosal Gland Cells by Adenovirus-Mediated and Cationic Lipidâ€“Mediated Gene Transfer. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 1107-1115.	1.4	7
60	Contribution of Plasmid DNA to Inflammation in the Lung after Administration of Cationic Lipid:pDNA Complexes. Human Gene Therapy, 1999, 10, 223-234.	1.4	199
61	Increased Duration of Transgene Expression in the Lung with Plasmid DNA Vectors Harboring Adenovirus E4 Open Reading Frame 3. Human Gene Therapy, 1999, 10, 1833-1843.	1.4	20
62	Cationic Lipid-Mediated Gene Delivery to the Airways. , 1999, , 39-68.		16
63	Efficiency of Cationic Lipid-Mediated Transfection of Polarized and Differentiated Airway Epithelial CellsIn VitroandIn Vivo. Human Gene Therapy, 1998, 9, 1531-1542.	1.4	81
64	Aerosolization of Cationic Lipid:pDNA Complexesâ€”In Vitro Optimization of Nebulizer Parameters for Human Clinical Studies. Human Gene Therapy, 1998, 9, 43-52.	1.4	31
65	Partial restoration of cAMP-stimulated CFTR chloride channel activity in Î”F508 cells by deoxyspergualin. American Journal of Physiology - Cell Physiology, 1998, 275, C171-C178.	2.1	82
66	Optimization of Formulations and Conditions for the Aerosol Delivery of Functional Cationic Lipid:DNA Complexes. Human Gene Therapy, 1997, 8, 313-322.	1.4	85
67	Basis of Pulmonary Toxicity Associated with Cationic Lipid-Mediated Gene Transfer to the Mammalian Lung. Human Gene Therapy, 1997, 8, 689-707.	1.4	239
68	A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung. Human Gene Therapy, 1997, 8, 765-773.	1.4	93
69	Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells. Human Gene Therapy, 1997, 8, 575-584.	1.4	116
70	Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung. Human Gene Therapy, 1996, 7, 1701-1717.	1.4	453
71	Generation and characterization of a Î”F508 cystic fibrosis mouse model. Nature Genetics, 1995, 10, 445-452.	9.4	215
72	Purification and Characterization of Recombinant Cystic Fibrosis Transmembrane Conductance Regulator from Chinese Hamster Ovary and Insect Cells. Journal of Biological Chemistry, 1995, 270, 17033-17043.	1.6	32

#	Article	IF	Citations
73	Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology, 1995, 108, 584-592.	0.6	42
74	Improved Cationic Lipid Formulations for In Vivo Gene Therapy. Annals of the New York Academy of Sciences, 1995, 772, 126-139.	1.8	249
75	Production of Cystic Fibrosis Transmembrane Conductance Regulator in the Milk of Transgenic Mice. Nature Biotechnology, 1992, 10, 74-77.	9.4	39
76	Cystic fibrosis transmembrane conductance regulator: A chloride channel with novel regulation. Neuron, 1992, 8, 821-829.	3.8	226
77	Intracellular protein trafficking defects in human disease. Trends in Cell Biology, 1992, 2, 145-149.	3.6	99
78	Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell, 1991, 66, 1027-1036.	13.5	651
79	Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature, 1990, 347, 358-363.	13.7	649
80	Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature, 1990, 347, 382-386.	13.7	337
81	Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell, 1990, 63, 827-834.	13.5	1,697